Trial · NCT06531109
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
NCT06531109, Active not recruiting, Pfizer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib. Trials, record NCT06531109. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06531109
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
- NCT number
- NCT06531109
- Status
- Active not recruiting
- Enrollment
- 450 participants, estimated
- Lead sponsor
- Pfizer
- Conditions
- Alopecia Areata
- Interventions
- Ritlecitinib
- First posted
- 2024-07-31
- Last updated
- 2026-11-06
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage change from baseline in Severity of Alopecia Tool (SALT) score at week 24 | 24 weeks from initiation of the treatment | SALT score is used to calculate the severity of alopecia areata. Physician calculate it by summing the percentage of hair loss in different regions of scalp. |
| Secondary | Demographic characteristic of participants: Age, sex, race, ethnicity, socio-economic status, area of residence, smoking status | Baseline | Number/percentage of patients by age, sex, race, ethnicity, socio-economic status, area of residence, smoking status. Race and ethnicity variables will only be collected in participating countries where it is allowed. |
| Secondary | Demographic Characteristic of Participants: Date of Initial AA diagnosis | Baseline | |
| Secondary | Demographic Characteristics of participants: Duration of AA since diagnosis | Baseline | |
| Secondary | Demographic characteristics of participants: Duration of current AA Episode | Baseline | |
| Secondary | Demographic Characteristic of Participants: Predominant AA phenotype | Baseline | Predominant AA phenotype (eg, patchy; ophiasis; AT; AU, etc |
| Secondary | Clinical Characteristics of participants: Severity of Alopecia Tool (SALT) Score | Baseline | SALT score is used to calculate the severity of alopecia areata. |
| Secondary | Clinical characteristics of participants: Eyelash Assessment (ELA) score | Baseline | ELA score is used to calculate the severity of the involvement of eyelashes. |
| Secondary | Clinical Characteristics of participants: Eyebrow Assessment (EBA) Score | Baseline | EBA score is used to calculate the severity of the involvement of eyebrows |
| Secondary | Clinical Characteristics of participants: number of affected nails | Baseline |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06531109
GET https://conductscience.org/api/trials/v1/NCT06531109/registered?page=2